title: Adjuvant endocrine therapy for breast cancer: don't ditch the switch!
authors.forename: Shannon
authors.initials: S
authors.lastname: Puhalla
authors.forename: Rachel C
authors.initials: RC
authors.lastname: Jankowitz
authors.forename: Nancy E
authors.initials: NE
authors.lastname: Davidson
mesh_terms: D000367:Age Factors; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D016889:Endometrial Neoplasms / Q000139:chemically induced*; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D015201:Meta-Analysis as Topic; D057285:Precision Medicine; D018570:Risk Assessment; D012307:Risk Factors; D016019:Survival Analysis; D013629:Tamoxifen / Q000627:therapeutic use; D013923:Thromboembolism / Q000139:chemically induced*; D016896:Treatment Outcome; D035501:Uncertainty
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D014408:Biomarkers, Tumor; D013629:Tamoxifen